Everolimus Aging Study (EVERLAST): Clinical Evaluation of mTORC1 Inhibition for Geroprotection

University of Wisconsin, Madison (registered trial) · · ClinicalTrials.gov (registration) · Atlas ID NCT05835999

What this study shows

Currently active phase 2 trial (NCT05835999) directly testing this Atlas's open dosing hypothesis: whether daily low-dose (0.5mg) versus weekly (5mg) everolimus can improve aging biomarkers and insulin resistance in humans without the metabolic penalty seen with continuous higher-dose rapalog use. No results yet - status ACTIVE_NOT_RECRUITING.

Abstract

ShowHide

The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans. Participants who are 55-80 years old and insulin resistant or prediabetic will be randomized to treatment and can expect to be on study for up to approximately 38 weeks; participants aged 18-35 will not receive the intervention and can expect to be on study up to approximately 8 weeks.

Read the full abstract →

At a glance

Evidence type	RT Registered trial, no results yet This is a registered clinical trial with no results reported yet. There is no evidence code until results are published -- registration alone is not evidence of an effect.
Study type	Registered Trial
Model system	Humans, RCT (registered, ongoing)
Journal	ClinicalTrials.gov (registration)
Year	—
Peer reviewed	No
Record last updated	2026-08-22
Source	DOI NCT05835999

Extracted findings

Intervention	Everolimus – daily 0.5 mg vs weekly 5 mg, 24 weeks
Target	mTORC1
Model	Human – RCT (registered, ongoing; age 55–80, insulin-resistant/prediabetic)
Effect	No results yet (ACTIVE_NOT_RECRUITING) – tests whether dosing improves aging hallmarks without metabolic penalty

In the Atlas

Cite this paper

ShowHide

University of Wisconsin, & Madison (registered trial) (n.d.). Everolimus Aging Study (EVERLAST): Clinical Evaluation of mTORC1 Inhibition for Geroprotection. ClinicalTrials.gov (registration). https://doi.org/NCT05835999

@article{NCT05835999,
  author       = {University of Wisconsin and Madison (registered trial)},
  title        = {{Everolimus Aging Study (EVERLAST): Clinical Evaluation of mTORC1 Inhibition for Geroprotection}},
  journal      = {ClinicalTrials.gov (registration)},
  doi          = {NCT05835999},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record NCT05835999) [Data set]. https://mtor-atlas.org/study/NCT05835999/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_NCT05835999,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record NCT05835999},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/NCT05835999/},
  doi          = {10.5281/zenodo.22059963}
}